Enjoy complimentary customisation on priority with our Enterprise License!
Below are some of the key findings from this testicular cancer drugs market analysis report
See the complete table of contents and list of exhibits, as well as selected illustrations and example pages from this report.
The availability of combination therapies for the treatment of testicular cancer is one of the critical reasons that will drive the testicular cancer drugs market’s growth. Combination therapy is preferred over single-drug therapy as its use has increased the survival rate to 95% in patients with testicular cancer. This therapy consists of two treatment regimens, namely etoposide, ifosfamide, and cisplatin combination therapy and bleomycin, etoposide, and cisplatin therapy. This has encouraged researchers from various institutes such as the Institute of Cancer Research to discover new combination therapies that can treat drug-resistant testicular germ cell cancer.
The development of novel treatment therapies by researchers has also encouraged the production of combinations of existing approved testicular cancer drugs. This will drive the testicular cancer drugs market to grow at a CAGR of over 4% during the forecast period. Researchers are studying chemotherapy drugs such as cabazitaxel and gemcitabine to treat testicular cancer. They are also studying an antibody-drug conjugate, brentuximab vedotin, that combines an anti-CD30 antibody with the drug monomethyl auristatin E.
The testicular cancer drugs market is fairly concentrated. Market vendors are focusing on developing advanced diagnostic methods for testicular cancer. By offering a complete analysis of the market’s competitive landscape and information on the products offered by the companies, this testicular cancer drugs industry analysis report will allow the clients to identify new growth opportunities and design innovative strategies to improve their share in the market.
The report offers a complete analysis of various companies including:
North America will contribute to the highest growth of the global testicular cancer drugs market throughout the forecast period. The growing awareness of testicular cancer through initiatives implemented by various organizations such as the Testicular Cancer Society and Testicular Cancer Foundation is one of the major reasons for high growth of the testicular cancer drugs market in this region.
Non-seminoma is a commonly occurring type of testicular cancer and the availability of effective drugs to treat patients with non-seminoma is also high. As a result, the non-seminoma segment will account for the highest market share in the testicular cancer drugs market.
We can help! Our analysts can customize this market research report to meet your requirements. Get in touch
PART 01: EXECUTIVE SUMMARY
PART 02: SCOPE OF THE REPORT
PART 03: MARKET LANDSCAPE
PART 04: PIPELINE ANALYSIS
PART 05: MARKET SIZING
PART 06: FIVE FORCES ANALYSIS
PART 07: MARKET SEGMENTATION BY TYPE
PART 08: CUSTOMER LANDSCAPE
PART 09: GEOGRAPHIC LANDSCAPE
PART 10: DRIVERS AND CHALLENGES
PART 11: MARKET TRENDS
PART 12: VENDOR LANDSCAPE
PART 13: VENDOR ANALYSIS
PART 14: APPENDIX
PART 15: EXPLORE TECHNAVIO
Get lifetime access to our
Technavio Insights
Quick Report Overview:
Cookie Policy
The Site uses cookies to record users' preferences in relation to the functionality of accessibility. We, our Affiliates, and our Vendors may store and access cookies on a device, and process personal data including unique identifiers sent by a device, to personalise content, tailor, and report on advertising and to analyse our traffic. By clicking “I’m fine with this”, you are allowing the use of these cookies. Please refer to the help guide of your browser for further information on cookies, including how to disable them. Review our Privacy & Cookie Notice.